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Alzheimer’s disease (AD) is characterized by extracellular neuritic plaques
composed of fibrillar β-amyloid (Aβ) peptide and intracellular neurofibrillary
tangles (NFTs). Multiple lines of evidence suggest that
overproduction/aggregation of A&#61538; in the brain is the major cause of AD
pathogenesis. Epidemiological studies indicate that long-term use of non-steroidal
anti-inflammatory drugs (NSAIDs) is associated with a reduced risk of AD
development. (R)-flurbiprofen, the R-enantiomer of flurbiprofen racemate, has
been found effective in reducing amyloid pathology in AD transgenic mouse
models and become a prospective candidate for AD treatment. Unfortunately, the
results from phase  clinical trials using (R)-flurbiprofen for AD treatment by Myrial
Genetics were disappointing. Thus, it is necessary to determine the mechanism
by which (R)-flurbiprofen exerts its anti-AD effects. In this study, we examined the
effect of (R)-flurbiprofen on expression of Aβ in N2a695 cells (a mouse
neuroblastoma cell line which overexpresses APP695). Our results showed that
(R)-flurbiprofen treatment reduced the levels of extracellular Aβ (including Aβ 40,
Aβ 42, and Aβ38), consistent with previous reports. Surprisingly, we found that
(R)-flurbiprofen treatment significantly increased the levels of intracellular
A&#61538;, which has been suggested to be more correlated with AD than
extracellular A&#61538;. Retinoid X receptor (RXR&#61537;) is a member of the
nuclear receptor superfamily, which can mediate the anti-tumor effects. In this
study, we found that downregulation of RXR&#61537; by siRNA significantly
increased the level of extracellular A&#61538; but had no effect on intracellular
A&#61538;. Moreover, The inhibitory effect of (R)-flurbiprofen on extracellular
A&#61538; was abolished upon downregulation of RXR&#61537;. In addition,
when APP was overexpressed in wild type N2a cells, there was a re-distribution













RXRα in the cytoplasm of AD patient brain cells was dramatically increased.
Together, our results demonstrate that (1) (R)-flurbiprofen reduces Ab secretion
but increases the levels of intracellular Ab, providing a possible explanation for
the failure of clinical trials of (R)-flurbiprofen for AD treatment; (2) RXR&#61537;
regulates A&#61538; secretion and is involved in (R)-flurbiprofen-mediated Ab
generation, suggesting that RXR&#61537; might be a potential target for AD drug
development; and (3) APP/Aβaffects the distribution of RXR&#61537;in
cytoplasm and nucleus.
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